VirtualScopics Awarded Contracts for Cancer Studies

VirtualScopics Inc., a developer of image-based biomarker solutions, announced today the signing of two, 24-month contracts totaling $1,400,000 for two Phase II/III cancer studies of the vascular disruptive agent MN-029 with MediciNova; a pharmaceutical company. In the agreement, VirtualScopics will perform site qualification and training for more than 110 global imaging sites, image data analysis and final reporting.
The studies include both standard CT tumor imaging and dynamic contrast enhanced MRI (DCE-MRI), an advanced imaging technique for directly measuring blood flow and vascular permeability in tumors.